Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease

Simple item page
dc.contributor.authorYılmaz, Yusuf
dc.contributor.authorYonal, Oya
dc.contributor.authorKurt, Ramazan
dc.contributor.authorAlahdab, Yeşim Özen
dc.contributor.authorÖzdogan, Osman
dc.contributor.authorÇelikel, Çiğdem Ataizi
dc.contributor.authorİmeryuz, Neşe
dc.contributor.authorKalaycı, Cem
dc.contributor.authorAvşar, Erol
dc.contributor.buuauthorUlukaya, Engin
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.researcheridK-5792-2018tr_TR
dc.contributor.scopusid6602927353tr_TR
dc.date.accessioned2021-12-29T09:38:36Z
dc.date.available2021-12-29T09:38:36Z
dc.date.issued2011-01
dc.description.abstractBackground and Aims. Vascular endothelial growth factor A (VEGF) is a multifunctional cytokine affecting angiogenesis and vascular function. The biological activity of VEGF is modulated by its soluble receptor VEGFR-1 (sVEGFR-1). We explored the associations of VEGF and sVEGFR-1 concentrations with liver histology in patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD). Methods. The study was comprised of 99 patients with NAFLD and 75 healthy controls. Serum VEGF and sVEGFR-1 concentrations were measured using commercially available enzyme-linked immunosorbent assays. Results. Serum VEGF levels did not differ in patients with NAFLD (1882 +/- 942 pg/mL) compared with healthy controls (1985 +/- 945 pg/mL, p = 0.42). However, compared with healthy subjects, levels of sVEGFR-1 were significantly lower in patients with NAFLD (1.59 +/- 0.58 ng/mL vs. 1.16 +/- 0.34 ng/mL, respectively, p < 0.001). After allowance for potential confounders, serum sVEGFR-1 levels retained their independent significance as a predictor of liver fibrosis in patients with NAFLD (beta = -0.19; t = -1.81, p < 0.05). Conclusions. Our results show that patients with biopsy-proven NAFLD have a significant reduction in serum sVEGFR-1 concentrations that predict the degree of liver fibrosis, independent of potential confounders.en_US
dc.description.sponsorshipMarmara Üniversitesi (SAG-C-TUP-090909-0274)tr_TR
dc.description.sponsorshipKaraciğer Hastalıkları Araştırma Derneğitr_TR
dc.identifier.citationYılmaz, Y. vd. (2011). ''Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease''. Archives of Medical Research, 42(1), 38-43.en_US
dc.identifier.endpage43tr_TR
dc.identifier.issn0188-4409
dc.identifier.issue1tr_TR
dc.identifier.pubmed21376261tr_TR
dc.identifier.scopus2-s2.0-79952084700tr_TR
dc.identifier.startpage38tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.arcmed.2010.12.001
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0188440910003486
dc.identifier.urihttp://hdl.handle.net/11452/23728
dc.identifier.volume42tr_TR
dc.identifier.wos000288589900007tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevier Scienceen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalArchives of Medical Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectResearch & experimental medicineen_US
dc.subjectVascular endothelial growth factoren_US
dc.subjectNonalcoholic fatty liver diseaseen_US
dc.subjectLiver fibrosisen_US
dc.subjectEnzyme-linked immunosorbent assayen_US
dc.subjectSteatohepatitisen_US
dc.subjectMetabolic syndromeen_US
dc.subjectPlasma levelsen_US
dc.subjectVEGFen_US
dc.subjectAngiogenesisen_US
dc.subjectAssociationen_US
dc.subjectSteatohepatitisen_US
dc.subjectHypertensionen_US
dc.subjectSFLT-1en_US
dc.subjectCellsen_US
dc.subjectRisken_US
dc.subject.emtreeVasculotropin Aen_US
dc.subject.emtreeVasculotropin receptor 1en_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeEnzyme linked immunosorbent assayen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreeLiver biopsyen_US
dc.subject.emtreeLiver fibrosisen_US
dc.subject.emtreeLiver histologyen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNonalcoholic fatty liveren_US
dc.subject.emtreeProtein blood levelen_US
dc.subject.meshAdulten_US
dc.subject.meshBiopsyen_US
dc.subject.meshFatty liveren_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLiveren_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshVascular endothelial growth factor aen_US
dc.subject.meshVascular endothelial growth factor receptor-1en_US
dc.subject.scopusFatty Liver; Proton Density (Concentration); Keratin-18en_US
dc.subject.wosMedicine, research & experimentalen_US
dc.titleCirculating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver diseaseen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus